Compare ONEW & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 186.7M |
| IPO Year | 2019 | 2002 |
| Metric | ONEW | KZIA |
|---|---|---|
| Price | $9.65 | $9.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $13.33 | ★ $28.36 |
| AVG Volume (30 Days) | 87.8K | ★ 286.0K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.85 | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $4.86 |
| 52 Week High | $17.35 | $17.40 |
| Indicator | ONEW | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 34.24 |
| Support Level | $9.04 | $9.01 |
| Resistance Level | $9.83 | $14.85 |
| Average True Range (ATR) | 0.61 | 0.69 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 40.89 | 10.25 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.